Loading
A phase 3 trial testing Naporafenib in melanoma, active and no longer recruiting.
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) is a phase 3 interventional study registered as NCT06346067, led by Erasca, and active but no longer recruiting on the registry. Official title: A Randomised, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]. Planned enrolment is 78 participants (actual). The study started in 2024-04-29 and primary completion is expected in 2028-04. No results have been posted on ClinicalTrials.gov.
Shares Naporafenib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.